| Literature DB >> 34550729 |
C Glenn Begley1, Mark Ashton2, Jonathan Baell3, Michael Bettess4, Michael P Brown5, Brett Carter6, William N Charman3, Christopher Davis7, Simon Fisher8, Ian Frazer9, Anand Gautam10, Michael P Jennings7, Philip Kearney11, Eloise Keeffe7, Darren Kelly12, Angel F Lopez13, Michael McGuckin14, Michael W Parker15, Craig Rayner16, Brett Roberts8, James S Rush17, Mark Sullivan18.
Abstract
Drug repurposing is promoted as a cost- and time-effective mechanism for providing new medicines. Often, however, there is insufficient consideration by academic researchers of the processes required to ensure that a repurposed drug can be used for a new indication. This may explain the inability of drug repurposing to fulfill its promise. Important aspects, often overlooked, include financial and intellectual property considerations, the clinical and regulatory path, and clinical equipoise, which provides ethical justification for randomized controlled trials. The goal of drug repurposing is to obtain a new regulator-approved label for an existing drug, and so, the trajectory for drug repurposing and traditional drug development is similar. Here, we discuss factors critical for a successful repurposed medicine to help academic investigators better identify drug repurposing opportunities.Entities:
Mesh:
Year: 2021 PMID: 34550729 DOI: 10.1126/scitranslmed.abd5524
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956